Bausch + Lomb (NYSE:BLCO) Raised to Hold at The Goldman Sachs Group

Bausch + Lomb (NYSE:BLCO) was upgraded by investment analysts at The Goldman Sachs Group to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

A number of other research analysts also recently commented on the stock. Wells Fargo & Company lifted their price objective on shares of Bausch + Lomb from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. Barclays cut their target price on shares of Bausch + Lomb from $19.00 to $16.00 and set an “equal weight” rating for the company in a research note on Monday, June 9th. Zacks Research upgraded Bausch + Lomb to a “hold” rating in a report on Tuesday, August 12th. Morgan Stanley boosted their price target on Bausch + Lomb from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Finally, Citigroup raised their price objective on Bausch + Lomb from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Wednesday, July 9th. Three research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $15.60.

Bausch + Lomb Stock Up 0.6%

NYSE:BLCO opened at $14.76 on Wednesday. Bausch + Lomb has a twelve month low of $10.45 and a twelve month high of $21.69. The firm has a market capitalization of $5.22 billion, a price-to-earnings ratio of -18.92, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63. The company has a quick ratio of 0.98, a current ratio of 1.55 and a debt-to-equity ratio of 0.76. The stock’s 50 day moving average price is $14.60 and its two-hundred day moving average price is $13.37.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.25 billion. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.13 EPS. Bausch + Lomb has set its FY 2025 guidance at EPS. Equities research analysts expect that Bausch + Lomb will post 0.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bausch + Lomb

A number of institutional investors have recently made changes to their positions in the company. Trexquant Investment LP grew its position in shares of Bausch + Lomb by 5.8% during the 1st quarter. Trexquant Investment LP now owns 20,255 shares of the company’s stock worth $294,000 after purchasing an additional 1,108 shares in the last quarter. Woodline Partners LP boosted its stake in shares of Bausch + Lomb by 0.5% in the first quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock valued at $4,536,000 after buying an additional 1,436 shares during the period. Blue Trust Inc. grew its position in Bausch + Lomb by 58.5% during the second quarter. Blue Trust Inc. now owns 4,502 shares of the company’s stock worth $59,000 after buying an additional 1,662 shares in the last quarter. Ridgewood Investments LLC acquired a new stake in Bausch + Lomb during the second quarter worth approximately $26,000. Finally, Gabelli Funds LLC increased its stake in Bausch + Lomb by 0.5% during the 2nd quarter. Gabelli Funds LLC now owns 444,000 shares of the company’s stock worth $5,776,000 after acquiring an additional 2,000 shares during the period. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.